drugset / Trial / NCT05545891

Aripiprazole in Body Focused Repetitive Behaviors

NCT05545891

Phase 2 Not yet recruiting 100 enrolled University of Chicago
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either aripiprazole or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Timeline

Start
2026-06
Primary completion
2027-12
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg